NovaBay Pharmaceuticals (NYSE:NBY) announced today that it closed its previously announced acquisition of skincare treatment developer Dermadoctor. Emeryville, California-based NovaBay develops the Avenova antimicrobial lid and lash spray, the CelleRx clinical reset and the NeutroPhase skin and wound cleanser for wound healing, all formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid. In September, the […]
Insulet posts Q3 sales beat, remains on track for Omnipod 5 clearance
Insulet (NSDQ:PODD) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth […]
Eyenovia enrolls first patient in Phase 3 trial for treating presbyopia
Eyenovia (NSDQ:EYEN) announced today that it enrolled the first patient in the second Phase 3 clinical trial for its MicroLine formulation. New York-based Eyenovia designed its MicroLine proprietary pilocarpine formulation for temporary improvement in near vision (presbyopia). The Vision-2 trial, a double-masked, placebo-controlled, cross-over superiority trial will treat 140 subjects with presbyopia, randomly assigning them […]
BD ticks up on Street-beating Q4, sets 2022 guidance range
BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]
Tandem nosedives after hours despite strong Q3, raised guidance
Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast. TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%. The […]
Prime Therapeutics to prefer Viatris’ interchangeable insulin biosimilar
Pharmacy benefit manager Prime Therapeutics announced today that it will prefer Viatris’ (NSDQ:VTRS) Semglee insulin biosimilar injection on its national formularies as part of the pharmacy benefit. In July, the FDA cleared the Semglee insulin glargine-yfgn injection, developed by Viatris in collaboration with Biocon Biologics, as a biosimilar for controlling high blood sugar in adults […]
Catalent beats The Street in Q1, raises revenue guidance
Catalent (NYSE:CTLT) shares dipped today despite first-quarter financial results that beat the consensus forecast. The Somerset, New Jersey-based company posted profits of $93 million, or 49¢ per share, on sales of $1.025 billion for the three months ended Sept. 30, 2021, for a 13.4% bottom-line gain on sales growth of 21.2%. Get the full story at […]
NovaBay prices $15M private placement
NovaBay Pharmaceuticals (NYSE:NBY) announced today that it entered into a securities purchase agreement, with proceeds of approximately $15 million. Emeryville, California-based NovaBay’s agreement with certain institutional investors occurred in connection with a private placement of 15,000 shares of a newly created Series B non-voting convertible preferred stock. The Series B preferred stock comes in at […]
Dexcom enlists celebrities to promote The Global Movement for Time in Range
Dexcom (NSDQ:DXCM) announced today that it will utilize some star power to boost The Global Movement for Time in Range. Musician, actor and philanthropist Nick Jonas, along with musician, actress, author and entrepreneur Patti LaBelle, will both use their platforms to promote the initiative The Global Movement for Time in Range was launched earlier this […]
Dexcom raises guidance ahead of G7 launch, FDA submission imminent
Dexcom (NYSE:DXCM) shares are up more than 9% today — a day after the company announced it will soon formally seek FDA clearance for its next-gen G7 system. The San Diego-based diabetes management technology developer yesterday evening posted profits of $70.9 million, or 71¢ per share, on sales of $650.2 million for the three months […]
